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Abstract
Introduction
Genetic constitution and inflammation both contribute to development of coronary artery
disease (CAD). Several CAD-associated single-nucleotide polymorphisms (SNPs) have
recently been identified, but their functions are largely unknown. We investigated the associ-
ations between CAD-associated SNPs and five CAD-related inflammatory biomarkers.
Methods
We genotyped 45 CAD-associated SNPs in 701 stable CAD patients in whom levels of high-
sensitivity C-reactive protein (hsRCP), interleukin-6, calprotectin, fibrinogen and comple-
ment component 3 levels had previously been measured. A genetic risk score was calcu-
lated to assess the combined risk associated with all the genetic variants. A multiple linear
regression model was used to assess associations between the genetic risk score, single
SNPs, and the five inflammatory biomarkers.
Results
The minor allele (G) (CAD risk allele) of rs2075650 (TOMM40/APOE) was associated with
lower levels of high-sensitivity C-reactive protein (effect per risk allele: -0.37 mg/l [95%CI
-0.56 to -0.18 mg/l]). The inflammatory markers tested showed no association with the
remaining 44 SNPs or with the genetic risk score.
Conclusions
In stable CAD patients, the risk allele of a common CAD-associated marker at the TOM-
M40/APOE locus was associated with lower hsCRP levels. No other genetic variants or the
combined effect of all variants were associated with the five inflammatory biomarkers.
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Introduction
Inflammation is of major importance for the development of coronary artery disease (CAD)
[1]. Inflammatory cells and signaling molecules contribute to the disease process by modu-
lating the arterial wall, promoting lipoprotein retention, plaque formation and possibly
destabilization [1]. Accordingly, several inflammatory biomarkers have been shown to pre-
dict cardiovascular outcome [2–5].
Over the past 10 years, large-scale genome-wide association studies (GWAS) have identified a
large number of single-nucleotide polymorphisms (SNPs) associated with CAD [6]. Combined
into genetic risk scores (GRS), these SNPs predict adverse cardiovascular events in various popula-
tions with and without prior cardiovascular disease [7–10]. Although the majority of loci identified
seem to act through induction of atherosclerosis, little is known about the underlying mechanisms.
The majority of CAD-associated SNPs are located in non-coding regions of the genome. Expres-
sion quantitative trait loci (eQTL) data indicate that the loci primarily exert their effect through reg-
ulation of nearby gene expression, but a large proportion of these genes have not previously been
linked to CAD or risk factors for CAD [11,12]. A functional network analysis performed by the
CARDIoGRAMplusC4D Consortium (as part of the largest GWAS meta-analysis available at the
time of initiation of our study) suggested that SNPs related to theAPOA1, IL6R,MRAS, and PLG
genes may act on CAD development by affecting pathways of acute phase response signaling [11].
However, it remains unknown whether these SNPs are associated with commonly used outcome-
associated biomarkers of inflammation such as high-sensitivity C-reactive protein (hs-CRP), inter-
leukin 6 (IL-6), calprotectin, fibrinogen, and complement component 3 (C3) [2–5].
Therefore, our primary aim was to investigate the association between APOA1-, IL6R-,
MRAS-, and PLG-linked SNPs, and hs-CRP, IL-6, calprotectin, fibrinogen, and C3. Secondar-
ily, we explored the individual associations of other CAD-associated risk SNPs and the effect
of all SNPs combined using a genetic risk score (GRS).
Methods
Design and study population
This was a cross-sectional study including patients with stable CAD. The entire cohort has pre-
viously been described in detail [13]. Briefly, 900 patients were recruited from the Western
Denmark Heart Registry between November 2007 and January 2011, and all patients had
CAD as verified by coronary angiography. At the time of enrollment, where blood samples
were obtained, patients were considered stable (i.e. no cardiovascular events or revasculariza-
tion procedures within the last 12 months).
From the entire cohort, substudies on inflammatory biomarkers were performed comprising
hs-CRP [14], IL-6 [14], calprotectin [14], fibrinogen [15,16], and C3 [15,16]. Patients included in
these substudies were younger, more often had diabetes, prior MI and prior coronary revasculari-
zation, whereas renal failure and antihypertensive medication was less common, compared with
patients not included. In total, one or more inflammatory markers were measured in 713 patients,
and DNA was available in 704 patients. All patients provided informed written consent. The proj-
ect was approved by The Central Denmark Region Committees on Health Research Ethics (record
number: 1-10-72-210-15) and by the Danish Data Protection Agency (record number: 1-16-02-
400-15).
Inflammatory marker measurements
Standardized blood sampling was performed in the outpatient clinic between 8 a.m. and 3 p.m.
Blood was sampled from the antecubital vein with patients in supine position after 30 minutes of
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rest using vacuum tubes, a large bore needle (19 G), and a minimum of stasis [13]. Blood for hs-
CRP analysis was analysed using the KoneLab 30i (ILS Laboratories Scandinavia, Allerød, Den-
mark). The measurement range for hs-CRP was 0.2–10.0 mg/l. In 27 patients, hs-CRP values
were outside this range (maximum CRP-value of 35.8 mg/l). These patients were excluded in
order to avoid bias from patients with subclinical infections which could potentially affect the
levels of the inflammatory markers measured. IL-6 analyses were performed using the Cobas1
6000 analyser, E module (Roche, Mannheim, Germany). Serum calprotectin was measured
using enzyme-linked immunosorbent assay (ELISA) (MRP 8/14 Calprotectin, Bu¨hlmann, Scho¨-
nenbuch, Switzerland). Fibrinogen was measured by the clotting method of Clauss using a KC
10TM coagulometer (Henrich Amelung GmbH, Lemgo, Germany). Complement C3 was deter-
mined by ELISA according to the manufacturer’s instructions (GenWay Biotech, Inc., San
Diego, CA, USA). The coefficient of variance was<5% for both calprotectin and C3 ELISA
assays.
SNP selection and genotyping
A thorough literature review of CAD risk loci was used to select the lead SNPs or relevant
proxies of 46 loci genome-wide significantly associated with CAD and/or myocardial infarc-
tion (MI) in populations of European ancestry [6]. This included CAD-associated lead SNPs
previously linked to the APOA1, IL6R, MRAS, and PLG genes by either eQTL data or physical
proximity [11].
DNA was obtained from whole blood and direct genotyping was performed on a Fluidigm Bio-
mark HD as previously described [17]. One SNP (rs17114036) failed on all chips and three samples
with less than 50% of SNPs successfully genotyped were excluded. Therefore, the final dataset con-
sisted of 45 SNPs in 701 patients. Overall call rate was excellent (31376/31545 = 99.5%) and consis-
tent for all SNPs, except for rs964184 (call rate: 570/701 = 81.3%). All genotypes were successfully
called in 559/701 = 79.7% of samples, whereas43 SNPs where successfully called in 697/701 =
99.4% of samples.
Statistical analysis
Patient characteristics are reported as mean ± standard deviation (SD), median (interquartile
range [IQR]) or numbers (percentage). Each SNP was coded as 0, 1, or 2 depending on the num-
ber of CAD risk alleles in the patient. Under the assumption of additive genetic effects, a multi-
variable linear regression model was used to test the association between the individual SNPs
and hs-CRP, IL-6, calprotectin, fibrinogen, and C3, respectively. Predefined covariates (age, sex,
diabetes, prior MI, current smoking, body mass index [BMI], and renal failure defined as esti-
mated glomerular filtration rate60 ml/min) were simultaneously added to the model. There-
fore, the beta coefficient of a SNP corresponds to the adjusted average effect per risk allele on the
inflammatory biomarker.
To test the combined effect of all CAD-associated SNPs a weighted GRS was calculated as
previously reported [17]. The GRS was calculated as the sum of the number of risk alleles in
each individual, weighted by the log of the odds ratio for CAD obtained from the original dis-
covery GWAS papers. In the rare case of a missing genotype, the average of the cohort (a num-
ber of 0–2) for that SNP was used to calculate the GRS (in order to avoid a value of zero). For
statistical analyses, GRS was standardized meaning that the beta coefficient of the GRS corre-
sponds to the adjusted effect on the inflammatory marker per SD increase in GRS.
In the primary analyses, we considered a conservative Bonferroni-corrected p-value<0.0025
as statistically significant (threshold: p = 0.05 / [4 SNPs × 5 inflammatory biomarkers]). When
evaluating the remaining CAD-associated SNPs and the GRS, the level of significance was
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adjusted accordingly (threshold: p = 0.05 / [46 × 5] = 2.2×10−4). All analyses were performed
using STATA version 13.1 (StataCorp, 4905 Lakeway Dr, College Station, TX, USA).
Results
Patient characteristics
A total of 701 patients were included in data analyses. Patient characteristics and numbers
included in each analysis are displayed in Table 1. Mean age was 64 ± 9 years (range: 32–85
years) and 558 (80%) were males. Prior MI, diabetes and renal failure were present in 627
(89%), 218 (31%), and 102 (15%) of the patients, respectively.
Presumed inflammation-related SNPs and inflammatory proteins
The association between presumed inflammation-related SNPs and hs-CRP, IL-6, calprotectin,
fibrinogen, and C3 is presented in Table 2. A weak association was observed between rs4845625
(IL6R) and C3 (mean adjusted effect per risk allele: 0.03 (95% CI 0.00–0.06) mg/ml, p = 0.04),
but it did not meet the Bonferroni-corrected threshold of significance. Neither rs4252120 (PLG)
rs964184 (APOA1), nor rs9818870 (MRAS) significantly affected the inflammatory markers
measured.
Remaining CAD-related SNPs and inflammatory proteins
The evaluation of the remaining CAD-related SNPs is presented in Table 3. Of these, a nomi-
nally significant association was observed for rs1561198 (VAMP5/VAMP8) with IL-6 and
Table 1. Patient characteristics.
hs-CRPa
(n = 484)
IL-6b
(n = 563)
Calprotectinb
(n = 543)
Fibrinogenc
(n = 700)
C3c
(n = 698)
Age 64 ± 9 64 ± 9 64 ± 9 65 ± 9 65 ± 9
Male sex 386 (80) 446 (79) 430 (79) 558 (80) 557 (80)
Prior MI 442 (91) 518 (92) 499 (92) 626 (89) 624 (89)
Prior PCI/CABG 471 (97) 544 (97) 524 (97) 672 (96) 670 (96)
Prior Stroke 25 (5) 25 (4) 25 (5) 37 (5) 37 (5)
Diabetes 107 (22) 140 (25) 135 (25) 218 (31) 218 (31)
Renal failured 66 (14) 77 (14) 76 (14) 102 (15) 102 (15)
Antihypertensive treatment 437 (90) 509 (91) 493 (91) 636 (91) 635 (91)
Statin treatment 448 (93) 519 (92) 501 (92) 635 (91) 634 (91)
Current smoking 98 (20) 117 (21) 113 (21) 150 (21) 150 (22)
Systolic BP (mmHg) 142 ± 20 142 ± 21 142 ± 20 142 ± 21 142 ± 21
Diastolic BP (mmHg) 83 ± 11 83 ± 11 83 ± 11 83 ± 11 83 ± 11
Body mass index (kg/m2) 27.6 ± 4.3 27.7 ± 4.4 27.8 ± 4.4 27.9 ± 4.3 27.9 ± 4.4
Creatinine (mM) 81 (71–93.5) 81 (71–93) 81 (71–93) 81 (71–93.5) 81 (71–94)
Data are presented as mean ± SD, median (IQR), or n (%).Abbreviations: BMI, body mass index; BP, blood pressure; CABG, coronary artery bypass graft
surgery; MI, myocardial infarction; PCI, percutaneous coronary intervention.
a Data on prior stroke, antihypertensive treatment, statin treatment, BP, and BMI were missing in 3, 1, 1, 25, and 2 individuals, respectively.
b Data on prior stroke, antihypertensive treatment, statin treatment, current smoking, BP, and BMI were missing in 4, 1, 1, 1, 28, and 2 individuals,
respectively.
c Data on prior stroke, antihypertensive treatment, statin treatment, current smoking, BP, and BMI were missing in 6, 2, 3, 1, 30, and 2 individuals,
respectively.
d Estimated glomerular filtration rate60 ml/min.
https://doi.org/10.1371/journal.pone.0180365.t001
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calprotectin; rs17609940 (ANKS1A) with C3; rs2075650 (TOMM40,APOE) with hs-CRP and
IL-6; rs264 (LPL) with C3; and finally rs599839 (SORT1) with fibrinogen. Only the association
between rs2075650 and hs-CRP met the Bonferroni-corrected threshold of significance. The
rs2075650 locus is displayed in Fig 1. Further analysis showed that mean level of hs-CRP in
wildtype homozygous (A/A), heterozygous (A/G), and risk allele homozygous (G/G) patients
were 1.38 mg/l (95% CI 1.25–1.52 mg/l), 0.96 mg/l (95% CI 0.79–1.13 mg/l), and 0.81 mg/l
(95% CI 0.52–1.10 mg/l), respectively (Fig 2), demonstrating a gene-related dose-response
effect.
GRS and inflammatory proteins
We found no associations between the GRS and hs-CRP, IL-6, calprotectin, fibrinogen, or C3
with results detailed in Fig 3.
Discussion
In the present study of patients with established CAD, we investigated the association between
45 lead SNPs from loci associated with CAD and five common biochemical markers of inflam-
mation. The main findings were; 1) for SNP rs2075650 in the TOMM40,APOE locus, the
established CAD-risk allele was significantly associated with lower hs-CRP levels, 2) No other
CAD-related SNPs were associated with the inflammatory marker levels, either measured as
individual SNPs or when combined into a GRS.
Previous GWASs have demonstrated a robust association between the rs2075650 G-allele
and an increased risk of CAD [11]. In a recent study based on the present cohort, subanalysis
also confirmed an association between rs2075650 and recurrent CAD events showing that an
increase in the number of CAD risk alleles was associated with a hazard ratio of 1.40 (95% CI
1.00–1.97) of the primary endpoint composed of cardiovascular death, myocardial infarction
and stable coronary revascularization [19]. Considering the well-established relationship
between increasing levels of hs-CRP and adverse cardiovascular outcome [20], it may be sur-
prising that the CAD risk allele of rs2075650 was associated with lower levels of hs-CRP in our
sample. However, our findings are consistent with results from several previous large popula-
tion-based cohort studies. In these studies, the same inverse relationship between the CAD
Table 2. Associations between presumed inflammation-related SNPs and inflammatory proteins.
Locus SNP Nearby
genes
Call
rate
(%)
RAF hs-CRP
Beta
(95% CI)
p Interleukin-6
Beta (95%
CI)
p Calprotectin
Beta (95% CI)
p Fibrinogen
Beta (95%
CI)
p Complement
C3
Beta (95% CI)
p
6q26 rs4252120 PLG 100 0.70 -0.01
(-0.16–
0.15)
0.92 -0.56 (-1.13–
0.02)
0.061 0.06 (-0.01–
0.14)
0.10 0.02 (-0.09–
0.14)
0.69 -0.01 (-0.04–
0.03)
0.72
1q21.3 rs4845625 IL6R 99.6 0.44 0.10
(-0.04–
0.25)
0.17 0.14 (-0.40–
0.68)
0.61 0.00 (-0.07–
0.07)
0.98 0.09 (-0.02–
0.19)
0.12 0.03 (0.00–
0.06)
0.042
11q23.3 rs964184 APOA1 81.3 0.15 0.15
(-0.05–
0.36)
0.14 0.05 (-0.71–
0.82)
0.89 0.04 (-0.06–
0.14)
0.45 -0.04 (-0.15–
0.07)
0.49 0.02 (-0.03–
0.06)
0.52
3q22.3 rs9818870 MRAS 99.9 0.18 -0.02
(-0.20–
0.15)
0.79 -0.24 (-0.91–
0.44)
0.49 -0.02 (-0.11–
0.06)
0.59 -0.04 (-0.17–
0.10)
0.59 -0.01 (-0.05–
0.03)
0.63
Beta is the adjusted mean difference measured per risk allele. Bold indicate that the SNP meets a nominal threshold of significance of p<0.05.
Abbreviations: hs-CRP, high-sensitivity C-reactive protein; RAF, risk allele frequency; SNP, single nucleotide polymorphism.
https://doi.org/10.1371/journal.pone.0180365.t002
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Table 3. Associations between remaining CAD-related SNPs and inflammatory proteins.
Locus SNP Nearby
genes
Call
rate
(%)
RAF hs-CRP
Beta
(95% CI)
p IL-6
Beta
(95% CI)
p Calprotectin
Beta (95%
CI)
p Fibrinogen
Beta (95%
CI)
p C3
Beta
(95% CI)
p
6p21.2 rs10947789 KCNK5 100 0.80 0.10
(-0.09–
0.29)
0.29 -0.23
(-0.92–
0.46)
0.51 0.00 (-0.09–
0.09)
0.95 0.01
(-0.12–
0.15)
0.85 0.01
(-0.03–
0.04)
0.68
7q22 rs10953541 BCAP29 100 0.76 -0.06
(-0.22–
0.11)
0.50 0.04
(-0.58–
0.66)
0.90 -0.02 (-0.10–
0.06)
0.64 -0.03
(-0.15–
0.09)
0.62 0.01
(-0.02–
0.04)
0.61
1p32.3 rs11206510 PCSK9 100 0.81 -0.06
(-0.24–
0.12)
0.50 0.25
(-0.40–
0.91)
0.45 0.05 (-0.04–
0.13)
0.27 0.01
(-0.12–
0.14)
0.85 0.01
(-0.02–
0.05)
0.53
19p13.2 rs1122608 LDLR 100 0.78 -0.05
(-0.22–
0.12)
0.56 0.14
(-0.50–
0.79)
0.66 0.03 (-0.05–
0.11)
0.49 0.06
(-0.07–
0.19)
0.37 0.02
(-0.02–
0.06)
0.27
7q32.2 rs11556924 ZC3HC1 100 0.63 -0.04
(-0.19–
0.12)
0.65 0.23
(-0.35–
0.80)
0.44 0.00 (-0.08–
0.07)
0.99 -0.03
(-0.14–
0.08)
0.62 0.00
(-0.03–
0.03)
0.99
6q23.2 rs12190287 TCF21 100 0.65 -0.13
(-0.28–
0.03)
0.10 0.00
(-0.58–
0.57)
0.99 0.02 (-0.05–
0.10)
0.52 -0.02
(-0.14–
0.09)
0.70 0.01
(-0.02–
0.04)
0.59
10q24.3 rs12413409 CYP17A1 100 0.90 -0.09
(-0.33–
0.14)
0.44 0.35
(-0.54–
1.23)
0.44 -0.04 (-0.16–
0.07)
0.46 -0.08
(-0.26–
0.10)
0.38 0.01
(-0.03–
0.06)
0.55
6p24.1 rs12526453 PHACTR1 99.9 0.69 -0.05
(-0.20–
0.10)
0.53 -0.12
(-0.69–
0.45)
0.67 0.04 (-0.04–
0.11)
0.33 -0.01
(-0.12–
0.10)
0.87 0.02
(-0.01–
0.05)
0.29
17p11.2 rs12936587 RASD1.
SMCR3.
PEMT
100 0.54 0.01
(-0.14–
0.17)
0.85 0.10
(-0.46–
0.66)
0.73 -0.02 (-0.09–
0.05)
0.65 -0.04
(-0.15–
0.07)
0.49 0.01
(-0.02–
0.04)
0.62
9p21.3 rs1333049 CDKN2BAS
(ANRIL)
99.9 0.51 -0.06
(-0.21–
0.08)
0.40 0.15
(-0.38–
0.69)
0.58 0.01 (-0.06–
0.08)
0.83 0.07
(-0.04–
0.17)
0.21 0.00
(-0.03–
0.03)
0.92
10q23 rs1412444 LIPA 99.9 0.34 0.00
(-0.15–
0.14)
0.98 -0.25
(-0.79–
0.30)
0.38 0.00 (-0.07–
0.07)
0.92 0.01
(-0.10–
0.12)
0.89 0.02
(-0.01–
0.05)
0.22
2p11.2 rs1561198 VAMP5.
VAMP8
100 0.48 -0.05
(-0.19–
0.09)
0.47 -0.58
(-1.10–-
0.05)
0.033 -0.09
(-0.15–-0.02)
0.014 0.00
(-0.11–
0.10)
1.00 -0.02
(-0.05–
0.01)
0.12
1q41 rs17465637 MIA3 99.9 0.77 -0.04
(-0.21–
0.13)
0.63 -0.18
(-0.81–
0.44)
0.56 0.01 (-0.07–
0.09)
0.82 -0.05
(-0.18–
0.07)
0.40 0.00
(-0.04–
0.03)
0.89
6p21.31 rs17609940 ANKS1A 99.7 0.78 0.06
(-0.12–
0.23)
0.53 0.34
(-0.30–
0.97)
0.30 -0.05 (-0.13–
0.03)
0.21 0.02
(-0.11–
0.15)
0.77 -0.05
(-0.08–-
0.02)
0.0044
4q31.22 rs1878406* EDNRA 100 0.15 0.20
(0.00–
0.40)
0.047 -0.11
(-0.84–
0.63)
0.77 0.03 (-0.06–
0.13)
0.48 0.01
(-0.14–
0.15)
0.94 -0.02
(-0.06–
0.02)
0.29
7p21.1 rs2023938 HDAC9 100 0.10 0.22
(-0.02–
0.47)
0.072 0.56
(-0.36–
1.49)
0.23 -0.06 (-0.18–
0.06)
0.31 0.00
(-0.17–
0.18)
0.96 0.00
(-0.05–
0.05)
0.92
19q13 rs2075650 TOMM40,
APOE
99.9 0.17 -0.37
(-0.56–-
0.18)
1.4×10−4 -0.73
(-1.45–-
0.02)
0.046 -0.06 (-0.15–
0.03)
0.19 0.05
(-0.10–
0.19)
0.54 0.00
(-0.04–
0.04)
0.94
17p13.3 rs216172 SMG6 99.7 0.38 0.00
(-0.15–
0.15)
0.99 -0.02
(-0.44–
0.40)
0.93 -0.04 (-0.11–
0.03)
0.26 0.06
(-0.05–
0.17)
0.31 -0.03
(-0.06–
0.00)
0.061
(Continued )
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Table 3. (Continued)
Locus SNP Nearby
genes
Call
rate
(%)
RAF hs-CRP
Beta
(95% CI)
p IL-6
Beta
(95% CI)
p Calprotectin
Beta (95%
CI)
p Fibrinogen
Beta (95%
CI)
p C3
Beta
(95% CI)
p
2q22.3 rs2252641 ZEB2 100 0.48 -0.11
(-0.26–
0.04)
0.14 0.30
(-0.26–
0.85)
0.30 0.01 (-0.06–
0.08)
0.75 0.05
(-0.06–
0.16)
0.38 -0.02
(-0.05–
0.01)
0.20
10p11.23 rs2505083 KIAA1462 100 0.43 0.12
(-0.03–
0.27)
0.13 0.11
(-0.44–
0.67)
0.69 0.00 (-0.08–
0.07)
0.89 0.10
(-0.01–
0.21)
0.072 -0.02
(-0.05–
0.01)
0.27
8p21.3 rs264 LPL 99.6 0.86 0.16
(-0.05–
0.38)
0.13 0.40
(-0.20–
1.00)
0.19 -0.03 (-0.13–
0.07)
0.54 -0.05
(-0.20–
0.10)
0.53 0.04
(0.00–
0.08)
0.049
5q31.1 rs273909 SLC22A4 100 0.12 -0.14
(-0.37–
0.09)
0.24 -0.26
(-1.13–
0.61)
0.56 -0.01 (-0.12–
0.10)
0.86 -0.16
(-0.33–
0.01)
0.063 0.00
(-0.05–
0.04)
0.93
14q32.2 rs2895811 HHIPL1 99.9 0.47 -0.02
(-0.17–
0.12)
0.76 -0.32
(-0.73–
0.10)
0.13 -0.01 (-0.08–
0.06)
0.79 0.03
(-0.08–
0.14)
0.55 0.01
(-0.02–
0.04)
0.69
8q24.13 rs2954029 TRIB1 100 0.52 -0.14
(-0.29–
0.01)
0.061 -0.40
(-0.95–
0.14)
0.15 -0.05 (-0.12–
0.02)
0.18 -0.04
(-0.15–
0.07)
0.50 -0.01
(-0.04–
0.02)
0.49
12q24.12 rs3184504 SH2B3 99.0 0.56 0.01
(-0.13–
0.16)
0.89 -0.25
(-0.78–
0.28)
0.35 -0.05 (-0.12–
0.02)
0.16 0.00
(-0.10–
0.11)
0.93 0.00
(-0.03–
0.03)
0.96
6q25.3 rs3798220 LPA 100 0.02 0.02
(-0.48–
0.52)
0.94 -0.81
(-2.81–
1.20)
0.43 -0.14 (-0.39–
0.11)
0.27 -0.02
(-0.41–
0.37)
0.92 -0.08
(-0.18–
0.03)
0.16
15q25.1 rs3825807 ADAMTS7 99.7 0.60 0.03
(-0.11–
0.18)
0.67 0.24
(-0.31–
0.78)
0.39 -0.01 (-0.08–
0.06)
0.79 0.05
(-0.06–
0.16)
0.35 0.01
(-0.02–
0.04)
0.52
6p21.33 rs3869109 HLA-C.
HLA-B
99.7 0.59 -0.09
(-0.23–
0.05)
0.22 0.18
(-0.35–
0.71)
0.50 0.06 (-0.01–
0.12)
0.10 -0.10
(-0.21–
0.00)
0.062 0.02
(-0.01–
0.04)
0.29
17q21.32 rs46522 UBE2Z 100 0.58 -0.10
(-0.25–
0.05)
0.19 -0.04
(-0.59–
0.51)
0.89 0.06 (-0.01–
0.13)
0.12 0.07
(-0.04–
0.18)
0.23 0.00
(-0.03–
0.02)
0.75
13q34 rs4773144 COL4A1 99.7 0.42 0.01
(-0.14–
0.16)
0.89 -0.25
(-0.82–
0.32)
0.38 -0.01 (-0.08–
0.07)
0.89 0.01
(-0.10–
0.12)
0.90 -0.03
(-0.06–
0.00)
0.083
9q34 rs495828 AB0 99.7 0.23 0.09
(-0.08–
0.26)
0.29 0.40
(-0.23–
1.03)
0.21 0.01 (-0.07–
0.09)
0.87 0.00
(-0.13–
0.12)
0.98 0.01
(-0.02–
0.05)
0.46
10q11.1 rs501120 CXCL12 100 0.88 -0.08
(-0.30–
0.14)
0.48 -0.25
(-1.07–
0.57)
0.56 0.10 (-0.01–
0.20)
0.076 -0.04
(-0.19–
0.12)
0.66 0.02
(-0.02–
0.07)
0.28
2p24.1 rs515135 APOB 99.9 0.83 0.10
(-0.09–
0.28)
0.31 0.69
(-0.01–
1.38)
0.053 0.05 (-0.04–
0.14)
0.26 -0.01
(-0.15–
0.13)
0.88 -0.01
(-0.05–
0.03)
0.54
1p13 rs599839 SORT1 100 0.78 0.15
(-0.03–
0.33)
0.10 0.21
(-0.45–
0.88)
0.53 0.06 (-0.02–
0.15)
0.16 0.14 (0.01–
0.28)
0.034 0.01
(-0.02–
0.05)
0.54
2p21 rs6544713 ABCG8 100 0.30 -0.04
(-0.20–
0.12)
0.62 0.06
(-0.53–
0.66)
0.83 -0.05 (-0.12–
0.03)
0.22 -0.02
(-0.13–
0.10)
0.80 -0.01
(-0.04–
0.02)
0.54
2q33.1 rs6725887 WDR12 100 0.17 -0.14
(-0.33–
0.05)
0.15 0.01
(-0.71–
0.74)
0.97 0.02 (-0.07–
0.11)
0.68 -0.08
(-0.22–
0.06)
0.29 0.01
(-0.03–
0.05)
0.54
(Continued )
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risk allele and lower levels of hs-CRP has also been observed in European Americans [21],
Australian twin families [22], Asians [23], and Hispanics [21] but not Afro-Americans [21].
Our work extends these findings by demonstrating an association in patients with established
CAD. The mechanistic explanation for this inverse association is currently unknown. The
marker rs2075650 is located in the TOMM40 gene, just upstream of APOE, and APOC1. The
CAD risk allele (G) has been associated with a range of other phenotypes including reduced
longevity [24], reduced BMI [25], increased low-density lipoprotein cholesterol (LDL-C)
[22,26], and an increased risk of Alzheimer’s disease [27]. Because of the relatively strong link-
age disequilibrium in the TOMM40/APOE locus, it has been suggested that the G-allele at
rs2075650 is in fact tagging causal variation in the APOE gene. The APOE encodes the apolipo-
protein E with three different isoforms (ε2, ε3, and ε4 defined by the combination of rs7412
and rs429358. Northwestern European ancestry (CEU): r2 = 0.02 and r2 = 0.20 with rs2075650,
respectively), of which the ε4 isoform has long been known to associate with LDL-C, Alzhei-
mer’s disease, and hs-CRP [28,29]. However, recent data suggest that the TOMM40/APOE
locus is genetically complex [30], and therefore it is plausible that the G-allele is tagging differ-
ent underlying causal variants with different effects on CAD risk and hs-CRP, a concept sup-
ported by Middleberg et al [22]. This would also be in line with the current understanding that
hs-CRP is not causally related to cardiovascular risk [31].
Some previous GWASs have explored the association between CAD-associated risk variants
and common inflammatory markers, of which the IL6R locus has been associated with several.
In studies of hs-CRP, the IL6R locus (rs4129267) was consistently, though moderately, associated
with hs-CRP levels (CEU: r2 = 0.54 with rs4845625) [32–34]. Furthermore, IL6R (rs4129267) has
been associated with plasma levels of fibrinogen and IL-6 [35–37]. Although we observed a nom-
inal association between the IL6R locus and C3, our study does not support a significant effect of
IL6R on the inflammatory response. Other CAD-associated loci have also emerged in GWASs of
inflammatory markers. A large study from the CHARGE (Cohorts for Heart and Aging Research
in Genetic Epidemiology) consortium demonstrated a significant association between fibrinogen
Table 3. (Continued)
Locus SNP Nearby
genes
Call
rate
(%)
RAF hs-CRP
Beta
(95% CI)
p IL-6
Beta
(95% CI)
p Calprotectin
Beta (95%
CI)
p Fibrinogen
Beta (95%
CI)
p C3
Beta
(95% CI)
p
4q32.1 rs7692387 GUCY1A3 100 0.83 -0.13
(-0.33–
0.07)
0.22 0.09
(-0.66–
0.85)
0.80 0.00 (-0.10–
0.10)
0.98 -0.05
(-0.19–
0.10)
0.51 -0.02
(-0.06–
0.02)
0.39
15q26.1 rs8039305 FURIN 99.7 0.51 -0.01
(0.16–
0.13)
0.85 0.27
(-0.28–
0.82)
0.33 -0.01 (-0.08–
0.06)
0.87 -0.03
(-0.14–
0.08)
0.56 0.03
(0.00–
0.06)
0.068
13q12.3 rs9319428 FLT1 99.7 0.33 0.00
(-0.15–
0.16)
0.96 0.24
(-0.33–
0.82)
0.41 -0.03 (-0.11–
0.04)
0.37 0.00
(-0.11–
0.12)
0.95 -0.01
(-0.04–
0.02)
0.66
11q22.3 rs974819 PDGFD 100 0.27 -0.04
(-0.20–
0.12)
0.62 0.18
(-0.42–
0.79)
0.55 0.03 (-0.05–
0.11)
0.45 0.02
(-0.10–
0.14)
0.75 -0.02
(-0.05–
0.01)
0.24
21q22.1 rs9982601 MRPS6 99.9 0.14 0.14
(-0.07–
0.35)
0.18 0.22
(-0.57–
1.01)
0.59 0.06 (-0.04–
0.16)
0.24 -0.02
(-0.17–
0.14)
0.84 0.03
(-0.01–
0.07)
0.16
Bold values indicate that the SNP meets a nominal threshold of significance of p<0.05.
*rs1878406 was genotyped as a C/T SNP.
Abbreviations: hs-CRP, high-sensitivity C-reactive protein; RAF, risk allele frequency; SNP, single nucleotide polymorphism.
https://doi.org/10.1371/journal.pone.0180365.t003
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and variants near LIPA (rs2250644) and SH2B3 (rs7310615) [36]. Although these variants are in
perfect linkage disequilibrium with the SNPs genotyped in our study (CEU: r2 = 1.00 for both),
we did not find evidence of such association. Other GWASs have also demonstrated weak associ-
ations between variants at the AB0 locus (rs657152 and rs8176704; CEU: r2 = 0.46 and r2 = 0.02
with rs495828) and IL-6 [34,37], and a Chinese GWAS of C3 found an association with rs115758
39 close to HLA-C (CEU: r2 = 0.02 with rs3869109) [38]. We were not able to confirm any of
these associations. Importantly, our study was not powered to detect very small effect sizes.
However, it is striking that none of our estimates indicated even a trend towards such rela-
tionships. Several explanations for these inconsistencies may exist. Some of the SNPs tagged
in prior GWASs display different allele frequencies compared with the CAD-associated lead
SNPs genotyped in our study and slightly different ancestral origins may possibly play a role
as well. However, another important explanation may relate to the fact that we included
patients with established CAD in contrast to prior studies performed in population-based
cohorts without known cardiovascular disease. Patients with CAD have an increased infla-
mmatory response compared with healthy subjects [2], either as the cause or as a conse-
quence of CAD. Therefore, causal genetic variants might not associate with the levels of
inflammatory biomarkers in cohorts where all patients are affected by CAD, although such
an association may be evident in community-based populations, where some patients likely
Fig 1. Recombination rate and linkage disequilibrium at the rs2075650 locus in the CEU population. Generated using SNAP (http://archive.
broadinstitute.org/mpg/snap/ldplot.php) [18].
https://doi.org/10.1371/journal.pone.0180365.g001
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have subclinical CAD. In this context, it is important to note that we included stable CAD
patients in our study. Ninety percent had previous MI occurring at least 12 months prior to
inclusion, thus making it less likely that prior MIs influenced the levels of inflammatory
biomarkers.
Calprotectin is suggested a new biomarker of CAD [39–41]. The expression of calpro-
tectin has been found at the site of plaque rupture and in macrophages of atherosclerotic
plaques and is considered an inflammatory marker of plaque instability [40,42]. To our
knowledge, the present study is the first to explore the association between calprotectin
and CAD-associated risk variants. Although none of the CAD-associated variants signifi-
cantly affected calprotectin levels, a trend was observed for rs1561198. This SNP is located
between the VAMP5 and VAMP8 genes, whose products are involved in different aspects
of vesicle trafficking including cytokine release and phagocytosis [43]. Hence, a link
between this locus and calprotectin levels may plausibly exist. However, further studies
with larger number of individuals are needed to confirm this hypothesis.
Our study has limitations. Because of the number of statistical tests performed, we applied a
conservative Bonferroni-corrected threshold of significance to reduce the risk of type I errors.
This, together with the moderate sample size in the context of common complex diseases,
reduces the power to detect small effect sizes, in particular for SNPs with low minor allele fre-
quencies and for hs-CRP, IL-6, and calprotectin, which were not assessed in all patients. There-
fore, our study should be considered as exploratory. We did not assess the presence of other
n=331 n=138 n=14
n=138 n=140
2
4
6
hs
−C
RP
 (m
g/l
)
XX XY YY
rs2075650
n=331
Fig 2. Distribution of hs-CRP levels stratified by the genotypes of rs2075650. Boxes and whiskers
indicate quartiles and adjacent values. Values outside the range of adjacent values are plotted as outliers.
Abbreviations: hs-CRP, high sensitivity C-reactive protein.
https://doi.org/10.1371/journal.pone.0180365.g002
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Fig 3. Scatterplots of the association between inflammatory markers and the standardized GRS. Abbreviations: GRS, genetic risk score; hs-CRP,
high-sensitivity C-reactive protein.
https://doi.org/10.1371/journal.pone.0180365.g003
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inflammatory conditions, which may also affect the levels of inflammatory biomarkers. In case
of bias, this would likely lead the associations towards the null, since no strong association
between the genotyped SNPs and any such conditions has been reported. Moreover, we per-
formed the statistical analyses assuming additive genetic effects of the risk alleles. Although
this assumption may be reasonable for most of the genetic loci investigated, some might better
fit a recessive model [44], which would affect the power of our analyses.
Conclusion
In the present study, a common CAD-associated variant at the TOMM40/APOE locus
(rs2075650) was significantly associated with lower levels of hs-CRP in patients with stable
CAD. Future studies using deep sequencing of the TOMM40/APOE locus in large clinical sam-
ples are warranted to determine if rs2075650 is truly causing opposite allelic effects on CAD
and hs-CRP, or if the opposite association is explained by underlying linkage disequilibrium
with several hidden functional variants of which some affect the development of CAD inde-
pendent of hs-CRP. None of the remaining variants, both assessed independently or combined
as a GRS, were associated with hs-CRP, IL-6, calprotectin, fibrinogen, or C3. Our findings may
suggest that the effect of these CAD-loci on CAD development does not act through pathways
significantly affecting these commonly used inflammatory biomarkers.
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